Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine.
Previous studies have shown that the intravenous administration of yohimbine, an alpha 2 antagonist, increases norepinephrine turnover and has related anxiogenic effects in humans. We herein report that yohimbine also increases plasma neuropeptide Y (NPY) in healthy human subjects. This finding is consistent with previous reports in animals, but contrasts with a previously reported study in humans. NPY is a 36 amino acid peptide neurotransmitter located in sympathetic and nonsympathetic nerve fibers, as well as in brain structures such as the locus coeruleus, where it is colocalized with norepinephrine. NPY has been shown to inhibit locus coeruleus neuronal firing, decrease norepinephrine release, and increase postsynaptic noradrenergic signal transduction. When administered centrally, NPY also has anxiolytic properties. This study therefore suggests that yohimbine challenge may be useful in assessing NPY and noradrenergic system interactions in neuropsychiatric disorders such as panic disorder or post traumatic stress disorder in which noradrenergic system dysfunction has been observed.
Rasmusson
A M
AM
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Southwick
S M
SM
Hauger
R L
RL
Charney
D S
DS
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000328:Adult; D006801:Humans; D008297:Male; D009478:Neuropeptide Y / Q000097:blood*; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects*; D015016:Yohimbine / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D009478:Neuropeptide Y; D018341:Receptors, Adrenergic, alpha-2; D015016:Yohimbine